A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
posted on 2020-06-04, 08:18authored byJie Zhang, Junlong Li, Qiufei Ma, Hongbo Yang, James Signorovitch, Eric Wu
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).